Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anika Therapeutics (ANIK) Debt to Equity (2020 - 2022)

Historic Debt to Equity for Anika Therapeutics (ANIK) over the last 7 years, with Q2 2022 value amounting to $0.02.

  • Anika Therapeutics' Debt to Equity fell 7436.39% to $0.02 in Q2 2022 from the same period last year, while for Jun 2022 it was $0.02, marking a year-over-year decrease of 7436.39%. This contributed to the annual value of $0.02 for FY2021, which is 6872.21% down from last year.
  • According to the latest figures from Q2 2022, Anika Therapeutics' Debt to Equity is $0.02, which was down 7436.39% from $0.02 recorded in Q1 2022.
  • Anika Therapeutics' Debt to Equity's 5-year high stood at $0.17 during Q2 2020, with a 5-year trough of $0.01 in Q3 2021.
  • Its 3-year average for Debt to Equity is $0.06, with a median of $0.05 in 2020.
  • Per our database at Business Quant, Anika Therapeutics' Debt to Equity plummeted by 6606.71% in 2021 and then plummeted by 8323.55% in 2022.
  • Anika Therapeutics' Debt to Equity (Quarter) stood at $0.05 in 2020, then crashed by 68.72% to $0.02 in 2021, then increased by 0.33% to $0.02 in 2022.
  • Its last three reported values are $0.02 in Q2 2022, $0.02 for Q1 2022, and $0.02 during Q4 2021.